Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination

View ORCID ProfileSara Carazo, View ORCID ProfileDanuta M. Skowronski, View ORCID ProfileMarc Brisson, Sapha Barkati, Chantal Sauvageau, Nicholas Brousseau, Rodica Gilca, Judith Fafard, Denis Talbot, Manale Ouakki, Vladimir Gilca, Alex Carignan, Geneviève Deceuninck, Philippe De Wals, View ORCID ProfileGaston De Serres
doi: https://doi.org/10.1101/2022.06.23.22276824
Sara Carazo
1Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sara Carazo
  • For correspondence: sara.carazo@inspq.qc.ca
Danuta M. Skowronski
2Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada
MD FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Danuta M. Skowronski
Marc Brisson
3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
4Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Brisson
Sapha Barkati
5Department of Medicine, Division of infectious diseases, McGill University Health Center, McGill University, Montreal, Quebec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Sauvageau
1Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
4Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Brousseau
1Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
4Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
MD MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodica Gilca
1Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
4Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Fafard
6Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Quebec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Talbot
3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
4Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manale Ouakki
1Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Gilca
1Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Carignan
7Department of microbiology and infectious diseases, Sherbrook University, Sherbrook, Quebec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geneviève Deceuninck
3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe De Wals
1Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
4Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaston De Serres
1Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
4Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gaston De Serres
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background We estimated the protection against the Omicron BA.2 variant associated with prior primary infection (PI) due to pre-Omicron or Omicron BA.1 virus, with and without mRNA vaccination.

Methods A test-negative case-control study was conducted among healthcare workers (HCWs) tested for SARS-CoV-2 in Quebec, Canada, between March 27 and June 4, 2022, when BA.2 predominated and was presumptively diagnosed. Logistic regression models compared the likelihood of BA.2 reinfection (second positive test ≥30 days after PI) among HCWs with history of PI and none to three doses of mRNA vaccine versus infection-naïve, unvaccinated HCWs.

Findings Among 37,732 presumed BA.2 cases, 2,521 (6.7%) and 659 (1.7%) were reinfections following pre-Omicron or BA.1 PI, respectively. Among 73,507 controls, 7,360 (10.0%) and 12,315 (16.8%) had a pre-Omicron or BA.1 PI, respectively. Pre-Omicron PI was associated with 38% (95%CI:19-53) reduction in BA.2 infection risk, with higher BA.2 protection among those also vaccinated with one (56%), two (69%) or three (70%) vaccine doses. Omicron BA.1 PI was associated with greater protection against BA.2 (72%; 95%CI:65-78), higher among two-dose vaccinated at 96% (95%CI:95-96) but not improved with a third dose (96%; 95%CI:95-97). Hybrid Omicron BA.1 PI plus two or three dose vaccine-induced protection persisted for five months post-infection.

Interpretation Twice-vaccinated individuals who experienced BA.1 infection were subsequently well-protected for a prolonged period against BA.2 reinfection and derived no meaningful added benefit against BA.2 from a third dose of mRNA vaccine.

Competing Interest Statement

SC, MO and GDS reports that the Ministère de la santé et des services sociaux du Québec gave financial support to their institution for this work during the conduct of the study. GDS received a grant from Pfizer for a Meningococcal B antibody seroprevalence study unrelated to the current work. RG reports personal fees from Abbie honorary for a conference on Respiratory Syncytial Virus burden in children unrelated to the current work. DT is supported by a research career award from the Fonds de recherche du Québec - Santé. JF reports grants from Ministry of health of Quebec for sequencing of SARS-CoV-2 positive samples and grants from Cancogen (Génome Canada) for sequencing of SARS-CoV-2 positive samples unrelated to the current work; and she is chair of the provincial genomic surveillance committee of SARS-CoV-2 (INSPQ, Québec). DMS reports grants paid to her institution and unrelated to current work from Public Health Agency of Canada, from Michael Smith Foundation for Health Research, from Canadian Institutes of Health Research and from BCCDC Foundation for Public Health. Others authors have nothing to disclosure.

Funding Statement

This work was supported by the Ministère de la santé et des services sociaux du Québec.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was conducted under the legal mandate of the National Director of Public Health of Quebec under the Public Health Act, granting a participant consent waiver. It was also approved by the Research Ethics Board of the Centre hospitalier universitaire de Québec-Université Laval.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The databases used in this study are a property of the Mininstry of Health of Quebec and were shared with the researchers under the legal mandate of the National Director of Public Health of Quebec under the Public Health Act, preventing data sharing with a third party. Aggregate data are available within the manuscript and the supplementary material.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted June 27, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination
Sara Carazo, Danuta M. Skowronski, Marc Brisson, Sapha Barkati, Chantal Sauvageau, Nicholas Brousseau, Rodica Gilca, Judith Fafard, Denis Talbot, Manale Ouakki, Vladimir Gilca, Alex Carignan, Geneviève Deceuninck, Philippe De Wals, Gaston De Serres
medRxiv 2022.06.23.22276824; doi: https://doi.org/10.1101/2022.06.23.22276824
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination
Sara Carazo, Danuta M. Skowronski, Marc Brisson, Sapha Barkati, Chantal Sauvageau, Nicholas Brousseau, Rodica Gilca, Judith Fafard, Denis Talbot, Manale Ouakki, Vladimir Gilca, Alex Carignan, Geneviève Deceuninck, Philippe De Wals, Gaston De Serres
medRxiv 2022.06.23.22276824; doi: https://doi.org/10.1101/2022.06.23.22276824

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (322)
  • Neurology (2785)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)